Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 50 of 151

  1. Dupilumab

    Regeneron UK Limited

    Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  2. Dupilumab

    Regeneron UK Limited

    Alopecia Areata

    phase 2 small molecule active

    2 trials

  3. Dupilumab (blinded)

    Regeneron UK Limited

    Eosinophilic Gastritis

    phase 2 small molecule completed

    1 trial

  4. Dupilumab 300Mg Solution for Injection

    Regeneron UK Limited

    Pruritus

    phase 2 small molecule completed

    1 trial

  5. Dupixent®

    Regeneron UK Limited

    Allergic Rhinoconjunctivitis

    phase 2 mab completed

    1 trial

  6. Durability of protection after single immunis... for Falciparum malaria

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  7. Durvalumab

    United Therapeutics Europe Ltd

    Stage IB Hepatocellular Carcinoma AJCC v8

    phase 2 mab active

    1 trial

  8. Durvalumab

    Syndax Pharmaceuticals

    Unresectable Intrahepatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  9. Durvalumab + Oleclumab

    MedImmune

    Stage III Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  10. Dynorphin 1 - 13

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  11. E-cigarettes

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 other completed

    1 trial

  12. E. coli ETVAX

    United Therapeutics Europe Ltd

    Diarrhea

    phase 2 mab completed

    1 trial

  13. E2007-G000-236

    Eisai Co.,

    Childhood Epilepsy

    phase 2 small molecule active

    1 trial

  14. E6005

    Organon Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  15. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    Cervical Cancer

    phase 2 mab active

    1 trial

  16. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    HPV-Associated Cervical Carcinoma

    phase 2 mab active

    1 trial

  17. E7080

    Eisai Co.,

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  18. E7090

    Eisai Co.,

    Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  19. E7386-G000-201

    Eisai Co.,

    colorectal cancer, melanoma, hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  20. E7386-J081-102

    Eisai Co.,

    Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor

    phase 2 small molecule active

    1 trial

  21. EAE 115

    Wuhan Createrna Science and Technology Co., Ltd

    Multiple myeloma patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor"

    phase 2 small molecule active

    1 trial

  22. EAE-2020/MM0107

    Wuhan Createrna Science and Technology Co., Ltd

    Newly diagnosed multiple myeloma

    phase 2 small molecule active

    1 trial

  23. EAE116

    Wuhan Createrna Science and Technology Co., Ltd

    Newly diagnosed patients with multiple myeloma and severe renal impairment

    phase 2 small molecule active

    1 trial

  24. EAE120

    Wuhan Createrna Science and Technology Co., Ltd

    newly diagnosed multiple myeloma

    phase 2 small molecule active

    1 trial

  25. EAE127

    Wuhan Createrna Science and Technology Co., Ltd

    Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  26. EAE128

    Wuhan Createrna Science and Technology Co., Ltd

    Newly diagnosed patients with multiple myeloma

    phase 2 small molecule active

    1 trial

  27. EAE140

    Wuhan Createrna Science and Technology Co., Ltd

    Primary Immune Thrombocytopenia

    phase 2 other active

    1 trial

  28. EB01 Cream Placebo

    Edesa Biotech

    Allergic Contact Dermatitis

    phase 2 small molecule completed

    1 trial

  29. EBV-TCR-T (YT-E001) cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 mab active

    1 trial

  30. EBV-specific T cells (EBV-CTLs)

    Evidence Based Cataract Study Group

    EBV-induced Lymphomas

    phase 2 mab completed

    1 trial

  31. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  32. ECLYPse

    Fondazione Telethon ETS

    Patients affected by mCRC harbouring BRAF V600E

    phase 2 small molecule active

    1 trial

  33. EDG-5506, EDG-5506

    Edgewise Therapeutics

    Becker Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  34. EDG-7500

    Edgewise Therapeutics

    Hypertrophic Cardiomyopathy

    phase 2 small molecule active

    1 trial

  35. EDGE-Lung

    Gilead Sciences Pty Limited

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  36. EDIT-101

    Editas Medicine

    Leber Congenital Amaurosis 10

    phase 2 small molecule active

    1 trial

  37. EDIT-301

    Editas Medicine

    Sickle Cell Disease

    phase 2 gene therapy active

    1 trial

  38. EDIT-301

    Editas Medicine

    Transfusion Dependent Beta Thalassemia

    phase 2 gene therapy active

    1 trial

  39. EDP-235

    ENANTA PHARMACEUTICALS INC

    COVID-19

    phase 2 small molecule completed

    3 trials

  40. EDP-305 1 mg

    ENANTA PHARMACEUTICALS INC

    Primary Biliary Cholangitis

    phase 2 small molecule completed

    1 trial

  41. EDP-305 1.5 mg

    ENANTA PHARMACEUTICALS INC

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial

  42. EDP-305 Dose 1

    ENANTA PHARMACEUTICALS INC

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  43. EDP-323 Dose Regimen 1

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    1 trial

  44. EDP-420 / Duration of Treatment - 3 days

    ENANTA PHARMACEUTICALS INC

    Community Acquired Pneumonia

    phase 2 small molecule active

    1 trial

  45. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus (RSV)

    phase 2 small molecule completed

    2 trials

  46. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus Infections

    phase 2 small molecule terminated

    1 trial

  47. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus

    phase 2 small molecule completed

    1 trial

  48. EDP-938

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    6 trials

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.